Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal Campus, Mölndal, Sweden.
Med Clin North Am. 2013 May;97(3):369-76. doi: 10.1016/j.mcna.2012.12.012. Epub 2013 Feb 1.
This article gives an updated account of the clinical application of cerebrospinal fluid (CSF) biomarkers for Alzheimer disease (AD). The clinically most relevant biomarkers, total tau, phospho-tau and Aβ42 are discussed, and how they may be used, together with other diagnostic investigations, to make a predementia diagnosis of AD. Recent findings in sporadic and genetic preclinical AD are also discussed and, more specifically, what the biomarkers have taught us on the sequence of events in the pathogenic process underlying AD.
本文介绍了脑脊液（CSF）生物标志物在阿尔茨海默病（AD）中的临床应用的最新进展。讨论了临床上最相关的生物标志物，总 tau、磷酸化 tau 和 Aβ42，以及如何将其与其他诊断研究相结合，对 AD 的痴呆前进行诊断。还讨论了散发性和遗传性 AD 临床前的最新发现，更具体地说，生物标志物让我们了解了 AD 潜在发病机制中事件的先后顺序。
Zotero 插件